Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
Currently serving at the WHO, Emer Cooke is set to return to the EMA later this year in the role of executive director. She will have to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.
ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.
Teva’s country head for its local Israeli operation has moved on, with Teva promoting his successor from within. Meanwhile, Doug Sommerville, the former head of Teva Canada, has taken a new role dedicated to efforts to tackle the accelerating COVID-19 crisis.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.